Biotechnology Industry · uk
Enabling T Cells to Precisely Eliminate Diseased Cells: T-Therapeutics Raises $133 Million to Advance Human Trials
The University of Cambridge spinout is preparing to bring two TCR bispecific therapies into clinical trials, targeting solid tumors and autoimmune diseases, respectively. With funding secured, the next hurdle is to demonstrate that its approach to recognizing diseased cells can work safely in humans.
One challenge in getting the immune system to eliminate diseased cells is giving it sufficiently precise recognition cues. UK biotechnology company T-Therapeutics is developing bispecific therapies based on T-cell receptors (TCRs). On November 5, it announced the completion of a $133 million Series B financing to advance its two lead programs in cancer and autoimmune diseases into human trials.
The round, equivalent to £100 million, was co-led by Advent Life Sciences and the British Business Bank. New investors included Johnson & Johnson’s JJDC, Samsara BioCapital, M-Ventures and Eli Lilly, with all existing major shareholders also participating. Cooley, which served as legal adviser on the transaction, separately confirmed that the oversubscribed financing had closed.
The therapies are designed to form a recognition bridge between diseased cells and T cells: one end uses an engineered TCR to recognize the target, while the other recruits T cells by binding to CD3. The company says its OpTiMus platform can generate fully human TCRs to develop therapies against targets originating inside cells, expanding the range of targets that drugs can recognize.
The two programs are pursuing different disease areas. The oncology program targets solid tumors, while the immune disease program aims to selectively eliminate pathogenic cells that drive chronic tissue inflammation, achieving what the company calls an “immune reset.” However, this remains a development goal. The announcement did not disclose specific molecular targets, priority indications or patient efficacy data.
The planned use of the funding also reflects the current stage: supporting both programs’ entry into clinical trials and obtaining initial human data to validate the therapeutic concept. The British Business Bank said it invested £15 million, with the transaction carried out by its subsidiary British Patient Capital. The bank previously held an indirect stake in the University of Cambridge spinout through Cambridge Innovation Capital Fund II.
As development shifts toward clinical trials, the company has appointed Kirsty Crame as Chief Development Officer, responsible for translational research and clinical development. She previously led early clinical programs at Medigene and Gadeta and has experience developing TCR therapies. Advent, the British Business Bank, JJDC and Samsara BioCapital will also each appoint a representative to the board as a non-executive director.
This financing provides resources for testing in humans, but it has yet to answer the central questions about efficacy and safety: can the therapies effectively eliminate target cells while avoiding damage to other cells or triggering an excessive immune response? The announcement did not provide trial start dates, designs or enrollment sizes. Whether the two programs can bridge the gap between molecular recognition and patient benefit will depend on subsequent clinical data.